Register a trial

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02019420




Registration number
NCT02019420
Ethics application status
Date submitted
18/12/2013
Date registered
24/12/2013

Titles & IDs
Public title
Tedizolid Phosphate (TR-701 FA, MK-1986) vs Linezolid for the Treatment of Nosocomial Pneumonia (MK-1986-002)
Scientific title
A Phase 3 Randomized Double-blind Study Comparing TR-701 FA and Linezolid in Ventilated Gram-positive Nosocomial Pneumonia
Secondary ID [1] 0 0
TR701-132
Secondary ID [2] 0 0
1986-002
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Pneumonia 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Other respiratory disorders / diseases
Infection 0 0 0 0
Other infectious diseases
Infection 0 0 0 0
Studies of infection and infectious agents

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Tedizolid phosphate
Treatment: Drugs - Linezolid

Experimental: Tedizolid phosphate IV - Ventilated HABP/VABP participants receive tedizolid phosphate 200 mg IV once daily for 7 days, or for 14 days for concurrent bacteremia.

Active comparator: Linezolid IV - Ventilated HABP/VABP participants receive linezolid 600 mg IV every 12 hours for 10 days, or for 14 days for concurrent bacteremia.


Treatment: Drugs: Tedizolid phosphate
Tedizolid phosphate IV 200 mg once daily

Treatment: Drugs: Linezolid
Linezolid IV 600 mg twice daily
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants With All-Cause Mortality in the Intent-to-Treat (ITT) Population
Timepoint [1] 0 0
Up to 28 days
Secondary outcome [1] 0 0
Number of Participants With All-Cause Mortality in the Microbiological Intent-to-Treat (mITT) Population
Timepoint [1] 0 0
Up to 28 days
Secondary outcome [2] 0 0
Clinical Response at Test of Cure (TOC) Visit in the Intent-to-Treat (ITT) Population
Timepoint [2] 0 0
7-14 days after end of therapy - TOC
Secondary outcome [3] 0 0
Clinical Response at Test of Cure (TOC) Visit in the Clinically-Evaluable (CE) Population
Timepoint [3] 0 0
7-14 days after end of therapy - TOC
Secondary outcome [4] 0 0
Number of Methicillin-Susceptible Staphylococcus Aureus (MSSA)-Infected Participants With All-Cause Mortality in the Microbiological Intent-to-Treat (mITT) Population
Timepoint [4] 0 0
Up to 28 days
Secondary outcome [5] 0 0
Number of Methicillin-Resistant Staphylococcus Aureus (MRSA)-Infected Participants With All-Cause Mortality in the Microbiological Intent-to-Treat (mITT) Population
Timepoint [5] 0 0
Up to 28 days
Secondary outcome [6] 0 0
Number of Participants With a Favorable Response at End-of-Therapy (EOT) Visit in the Microbiological Intent-to-Treat (mITT) Population
Timepoint [6] 0 0
1-3 days after completing study therapy (Days 8-10 or Days 15-17)
Secondary outcome [7] 0 0
Number of Participants With a Favorable Response at End-of-Therapy (EOT) Visit in the Microbiologically-Evaluable 1 (ME-1) Population
Timepoint [7] 0 0
1-3 days after completing study therapy (Days 8-10 or Days 15-17)
Secondary outcome [8] 0 0
Number of Participants With a Favorable Response at Test-of-Cure (TOC) Visit in the Microbiological Intent-to-Treat (mITT) Population
Timepoint [8] 0 0
7-14 days after end of therapy - TOC
Secondary outcome [9] 0 0
Number of Participants With a Favorable Response at Test-of-Cure (TOC) Visit in the Microbiologically-Evaluable 2 (ME-2) Population
Timepoint [9] 0 0
7-14 days after end of therapy - TOC
Secondary outcome [10] 0 0
Number of Participants With =1 Adverse Events (AEs)
Timepoint [10] 0 0
Up to 32 days
Secondary outcome [11] 0 0
Number of Participants Discontinuing Study Therapy Due to an Adverse Event (AE)
Timepoint [11] 0 0
Up to 14 days

Eligibility
Key inclusion criteria
* Requires IV antibiotic therapy with diagnosis of ventilated nosocomial pneumonia
* Gram-positive bacteria on respiratory Gram stain
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Pneumonia of community, viral, fungal or parasitic etiology
* Structural lung abnormalities
* Immunosuppression
* Previous antibiotics for > 24 hours
* Expected survival of < 72 hours

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
6/01/2014
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
22/06/2018
Sample size
Target
Accrual to date
Final
726
Recruitment in Australia
Recruitment state(s)

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Medical Director
Address 0 0
Merck Sharp & Dohme LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
When will data be available (start and end dates)?
Available to whom?
Available for what types of analyses?
How or where can data be obtained?
IPD available at link: http://engagezone.msd.com/ds_documentation.php


What supporting documents are/will be available?




Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results are available at https://clinicaltrials.gov/study/NCT02019420